PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received ...

Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of demyelination in MS.

A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence ...

PTD802 is aimed at promoting remyelination in individuals with neurological conditions, particularly multiple sclerosis. Credit: New Africa/Shutterstock. Pheno Therapeutics has gained clinical trial ...

A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence agreement ...